Table 2 Patient Characteristics of the COEUR cohort
From: Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers
Histotypes | HGSC | EC | LGSC | CCC | MC | Total | |
|---|---|---|---|---|---|---|---|
Number of samples per histotypes | 1246 | 296 | 102 | 259 | 88 | 1991 | |
Age diagnosis (years) | Mean | 62 | 58 | 53 | 56 | 53 | 60 |
Age end of follow-up (years) | Mean | 66 | 63 | 59 | 61 | 58 | 64 |
Follow-up time (months) | Mean | 47 | 64 | 60 | 58 | 52 | 51 |
Min-Max | 0–211 | 0–268 | 0–270 | 0–247 | 1–228 | 0–270 | |
Total N | 1240 | 294 | 102 | 258 | 87 | 1983 | |
Stage | 1 | 70(6%) | 145(54%) | 13(14%) | 127(52%) | 61(74%) | 416 |
2 | 137(12%) | 74(28%) | 7(7%) | 54(22%) | 11(13%) | 283 | |
3 | 835(72%) | 45(17%) | 67(72%) | 58(23%) | 8(9%) | 1013 | |
4 | 123(11%) | 5(2%) | 6(6%) | 7(3%) | 3(3%) | 144 | |
Total N | 1165 | 269 | 93 | 246 | 83 | 1856 | |
Residual Disease | none | 207(28%) | 120(75%) | 16(22%) | 93(68%) | 36(81%) 472(36%) | |
< 1 cm | 231(31%) | 29(18%) | 21(32%) | 26(19%) | 4(10%) 310(24%) | ||
suboptimal | 387(47%) | 11(7%) | 27(41%) | 17(12%) | 4(10%) 110(8%) | ||
Total | 824 | 160 | 64 | 136 | 44 | 1311 | |
BRCA1 and BRCA2 mutation status | Mutation status known but not identified (%) | 1(< 1%)) | 0 | 1(3%) | 0 | 0 | 2(< 1%) |
BRCA1 Carriers (%) | 68(14%) | 0 | 2(6%) | 0 | 0 | 70(12%) | |
double BRCA1/BRCA2 carrier (%) | 4(< 1%) | 0 | 0 | 0 | 0 | 4(< 1%) | |
BRCA2 carriers (%) | 35(7%) | 0 | 1(3%) | 0 | 0 | 36(6%) | |
Non carriers (%) | 370(76%) | 44(100%) | 31(89%) | 25(100%) | 6(100%) | 476(80%) | |
Carriers of variants of unknown significance | 10(2%) | 0 | 0 | 0 | 0 | 10(< 2%) | |
Total BRCA mutation carrier | 108 | 0 | 4 | 0 | 0 | 112 | |
Survival rate | Alive | 386(32%) | 227(83%) | 45(45%) | 148(59%) | 63(73%) | 869(45%) |
Deceased | 830 | 47 | 56 | 107 | 23 | 1063 | |
Total | 1216 | 274 | 101 | 255 | 86 | 1932 | |
5-years survival rate | Alive | 353(34%) | 138(80%) | 46(54%) | 118(57%) | 34(65%) | 689(44%) |
Deceased | 678 | 35 | 39 | 89 | 18 | 859 | |
Total | 1031 | 173 | 85 | 207 | 52 | 1548 | |
Response to treatmenta | sensitive | 421(68%) | 27(73%) | 29(60%) | 16(44%) | 4(57%) | 497(66%) |
resistant | 201 | 10 | 19 | 20 | 3 | 253 | |
Total | 622 | 37 | 48 | 36 | 7 | 750 | |
Chemotherapy before first progression | none | 22(2%) | 35(14%) | 8(67%) | 15(6%) | 37(53%) | 117(7%) |
carbo+taxol | 955(81%) | 184(74%) | 66(67%) | 195(82%) | 31(40%) | 1431(78%) | |
cispl+taxol | 71(62%) | 8(3%) | 10(11%) | 6(3%) | 0 | 95(5%) | |
platinum | 63(5%) | 14(6%) | 7(7%) | 13(5%) | 3(4%) | 100(6%) | |
platinum+other | 38(3%) | 6(2%) | 5(6%) | 6(2.5%) | 1(1%) | 56(3%) | |
taxol | 3(< 1%) | 0% | 0 | 0 | 0 | 3(< 1%) | |
other | 17(1%) | (< 1%) | 0 | 3(1%) | 1(< 1%) | 22(1%) | |
Total | 1169 | 248 | 96 | 238 | 73 | 1824 | |
Long term survivors (> 10 years) | yes | 73(8%) | 38(45%) | 10(16%) | 23(18%) | 7(23%) | 151(13%) |
no | 818 | 47 | 54 | 102 | 23 | 1044 | |
Total | 891 | 85 | 64 | 125 | 30 | 1195 |